Infection preventionists and laboratorians: Case studies on successful collaboration

Maureen Spencer RN, BSN, Med, CIC, Denise Uettwiller-Geiger PhD, DLM (ASCP), Jennifer Sanguinet MBA-HCM, BSIS, CIC, Helen Boehm Johnson MD, Denise Graham

Corporate Director of Infection Prevention, Universal Health Services, King of Prussia, PA
Director of Laboratory Services and Clinical Trials, John T. Mather Hospital, Port Jefferson, NY
Director of Infection Prevention, West Hills Hospital and Medical Center, West Hills, CA
Freelance Medical Writer, Vero Beach, FL
Founder and CEO, DDG Associates, Alexandria, VA

Key Words:
Infection prevention
infection control
clinical laboratory
hospital-acquired infection
polymerase chain reaction

Efforts to reduce the incidence of hospital-acquired infection (HAI) remain a significant focus for health care facilities, particularly in this era of drug-resistant organisms. With as many as 1 in every 25 hospitalized patients acquiring an infection, the need to minimize the risk of HAIs is widely recognized as critical. Advances in the fields of biomedical technology, microbiology, pharmacology, and infection control and prevention, among others, have played a tremendous role in these efforts. However, evidence suggests that a key element in this battle against HAIs is missing: collaboration and communication between these groups in health care facilities—particularly in microbiology and infection prevention.

A 2012 survey of infection preventionists (IPs) and laboratory professionals conducted by the Association for Professionals in Infection Control and Epidemiology (APIC) and American Society for Microbiology revealed that 70% of those surveyed “would value assistance in relationship building between the two groups,” 83% would like to hear “about other facilities’ experience in creating partnerships,” and 78% would like “more education about best practices.” A recent focus group of IPs and laboratorians convened during the 2015 APIC conference and corroborated these sentiments with one IP stating that his IP colleagues “had never been to a laboratory...these were nurses that were on the floors for years and they were scared to death” (J. Sutton, personal communication, June 28, 2015).

IPS AND LABORATORIANS: PAST TO PRESENT

The laboratory has always been an integral part of infection prevention efforts, despite not getting formal recognition as such until the Society for Healthcare Epidemiology of America published their 1996 consensus panel report on requirements for infrastructure and essential activities of infection control and epidemiology in hospitals. The role of the laboratorian in infection prevention remains at the core of what it has always been: to provide timely analysis of specimens for infection detection. However, in this era of multidrug-resistant organisms, that role has grown far beyond simply...
identifying the presence or absence of a pathogen. Today’s labora-
torian, for example, is responsible for molecular typing of pathogens, 
recognition of patterns of antimicrobial resistance, antibiogram de-
velopment, and surveillance and application of new technologies, 
among others.8 Although their statement predated some of the most 
modern laboratory technologies and multidrug-resistant organ-
isms, Peterson and Brossette articulated the significant role 
laboratorians play in infection control when they wrote:

The necessary contribution from the laboratory includes sur-
veillance, providing for a systematic observance and measurement 
of disease, as well as molecular typing of microbial patho-
gens.” Present and future needs for laboratory-based surveil-
ance will require reliable detection of new pathogens that emerge as 
causes of important health care-associated infections, which 
implies accurate identification of microbial organisms; recog-
nition of new or emerging antimicrobial agent resistance; and 
participation in active surveillance for outbreaks. This contri-
bution dictates a strong collaboration between the hospital 
epidemiologist and the clinical microbiologist, with a conse-
quent positive impact on both the infection control program and 
the diagnostic laboratory. Such cooperation will be needed as 
we move to a future where pathogens of concern not only spread 
within the hospital but have the potential to affect both inpa-
ients and outpatients, healthcare workers, and their households.7

The relationship between laboratorians and IPs has also changed 
significantly since the advent of electronic medical records. Tradi-
tionally, IPs would begin their days rounding in the laboratory to 
gather information on the most recent positive cultures and sus-
cceptibility results. This face-to-face time facilitated a natural 
opportunity for communication between the 2 departments. Ad-
vances in information technology and the widespread adoption of 
electronic medical records, although arguably beneficial to the de-

delivery of health care at large, have ironically made communication 
between the laboratory and the infection prevention department 
significantly less interactive. If results can be accessed by comput-
er without any direct interface between IPs and laboratorians, the 
opportunity for the prompt exchange of information regarding early 
signs of potential cluster outbreaks is lost unless either group ini-
tiates communication with the other. Additionally, many facilities 
have consolidated laboratory services off-site, creating yet another 
obstacle for direct communication.

Laboratorians face their own internal need for collaboration as 
the lines of distinction between the clinical chemistry and clinical 
microbiology laboratories blur. The implementation of new tech-
nologies, ranging from chemiluminescent immunoassays to 
molecular dianostics, has created significant overlap between the 
2 fields, requiring the 2 departments to work cooperatively in max-
imizing testing efficiency and minimizing redundancy.5 Although the 
thoretical need for improved communication and collaboration 
between IPs and laboratorians has been widely recognized through-
out the health care community, many hospitals find themselves 
struggling to achieve this goal. Some facilities, however, have been 
successful in these efforts, and the results have been striking.

CASE IN POINT: J.T. MATHER HOSPITAL

In 2008, J.T. Mather Hospital, a 248-bed community hospital in 
New York State, initiated a campaign against methicillin-resistant 
Staphylococcus aureus (MRSA) that was initially a product of the part-
nership between their laboratory and infection prevention team and, 
ultimately, all levels of the hospital infrastructure, from the c-suite 
to the environmental services department. Recognizing that each 
medically incurred MRSA infection costs a hospital between $35,000 
and $60,000,2 the hospital wanted to address the most efficient and 
effective means of MRSA prevention. The goals identified by the lab-
atory and the infection prevention department were to rapidly 
identify colonized and infected patients, implement appropriate 
contact precautions and isolation, reduce turnaround times, stream-
line laboratory processes, and create a proactive rather than reactive 
environment.

Working together, the laboratory and infection prevention de-
partment evaluated the hospital’s existing testing algorithms and 
isolation protocols and determined that they needed to initiate a 
rapid active surveillance program targeting high-risk groups using 
on-demand polymerase chain reaction (PCR) technology. They agreed 
that the sensitivity and specificity of the test along with the fact 
that results could be made available in <2 hours were key to pro-
viding actionable information to clinicians as rapidly as possible. 
Armed with statistics regarding the incidence and costs of MRSA 
infections along with the data supporting the use of rapid active 

surveillance with on-demand PCR, the departments successfully 
lobbied their c-suite in the acquisition of the on-demand PCR equip-
ment. They then embarked on an education campaign with every 
department from nursing to pharmacy to environmental services, 
recognizing that these were the individuals on the front lines of col-
clecting samples, advising treatment options, and performing the end 
termal cleaning of rooms.

The campaign, entitled “The Bug Stops Here,” launched in 2008 
and has had significant clinical and financial results. The hospital has 
seen an 84% reduction in MRSA infection rates (74 infections 
in 2007; 12 infections in 2014) and an 84% reduction in hospital 
costs attributed to MRSA infection.6 Between 2008 and 2014, ap-
proximately 13,000 patients were tested using on-demand PCR 
(available 24 h/d, 7 d/wk) at a fully burdened cost of roughly $51 
per test, resulting in a total cost to the laboratory of $650,000 over 
those 7 years. However, using the low end estimate of each MRSA 
infection’s cost to a hospital ($35,000), the savings to the hospital for 
the 62 fewer infections was $1.5 million.7 Additionally, the hospital 
paid its average length of stay in the intensive care unit or 
coronary care unit reduced from 4.4 days to 3.3 days over the course 
of the campaign, resulting in another $500,000 in annual savings.8

Overall, the hospital saw an increase in operational efficiency, 
patient safety, and patient satisfaction, with a decrease in delays, 
labor, readmissions, Centers for Medicare and Medicaid Services 
(CMS) penalties, and MRSA HAIs. These results, according to Dr. 
Denise Uettwiller-Geiger, Clinical Chemist and Director of Clinical 
Trials at J.T. Mather Hospital, were realized because “all stakehold-
ers saw open communication and collaboration as being paramount 
to achieving success.”

She went on to say, “By coming together and breaking down those silos...we’ve been 
able to decrease hospital acquired infections...to improve opera-
tional efficiency because we know how to cohort our patients 
more effectively and also how to move them more effectively 
through the organization to the appropriate level of care from 
the moment they hit the portal of the emergency room where 
80% of our patients come from all the way down to discharge 
planning. We’ve been able to improve patient safety...decrease...or 
avoid those penalties from CMS (Centers for Medicare and Med-
caid Services)... [and] decrease laboratory labor because we have 
integrated this technology of molecular diagnostics into an ex-
isting workstation” (D. Uettwiller-Geiger, personal communication, 
June 2015).

CASE IN POINT: WEST HILLS HOSPITAL AND MEDICAL CENTER

As a 250-bed, semi-private room, community hospital sur-
rounded by a number of long-term care facilities, West Hills Hospital
has grappled with the problem of identifying *Clostridium difficile* infection and carrier status in patients presenting with diarrhea. Given the high incidence of patients who do present with diarrhea and the hospital’s policy of isolating all such patients, the need for rapid diagnosis of *C difficile* is urgent. The facility’s laboratory department, however, is comprised of 1 microbiologist along with laboratory technicians, making the handling of complicated *C difficile* testing algorithms, including enzyme immunoassay (EIA) and glutamate dehydrogenase/toxin (GDH) onerous at best. Although positive EIA results are reliable and obtainable the same day, negative results require outsourcing to a second party expert laboratory for a confirmatory test, potentially adding days to the time to diagnosis. Similarly, negative GDH results provide relatively reliable same day answers, but positive GDH results, given their low specificity, require additional testing—again adding to the time to diagnosis.

Having identified that these algorithms and protocols were significantly impacting their facility’s ability to expedite *C difficile* diagnosis and increase patient throughput, their infection prevention director and laboratory director partnered to determine a solution. Analysis of the hospital’s data revealed that on average there were 12 patient isolations a day for vancomycin-resistant *Enterococcus*, MRSA, and *C difficile*, with an average daily cost of $2,149 per medical-surgical bed, leading to approximately $9.4 million spent annually on blocked beds. They postulated that eliminating just a fourth of those patients each day could save the hospital $2.3 million. Although these numbers reflected isolation days for all patients, 40% of isolations were for suspected *C difficile*. Coupling these numbers with the constraints and delays posed by their current laboratory algorithms, the 2 departments determined that a transition to the highly sensitive and specific, user-friendly (eg, no laboratory expertise required), on-demand PCR technology offered their facility the best option for streamlining productivity. Furthermore, they calculated that clearing 1 patient for 1 day would cover the expense of testing 70 additional patients with on-demand PCR (at the estimated rate of $30 per test) (J. Sanguinet, unpublished raw data, 2015). Armed with these numbers, they embarked on a campaign to lobby their c-suite for acquisition of the technology—an acquisition that the c-suite agreed to this year. They additionally partnered to limit what they view as unnecessary testing, by proposing a restriction on *C difficile* tests ordered such that if EIA or PCR is ordered twice within a 7-day period, the laboratory will have the authority to cancel the second test. That proposition has now become laboratory policy.

**CASE IN POINT: UNIVERSAL HEALTH SERVICES**

When the new director of corporate infection arrived at Universal Health Services (UHS) in 2011, she brought with her the experience of including the head of the microbiology laboratory on every infection prevention committee at her former facility. She refers to essentially having marketed the laboratory director such that everyone involved in infection control, from IPs to surgeons, would build a relationship with the director and thereby have a direct conduit to the laboratory. Hence, one of her first items of business at UHS was establishing a relationship with the laboratory directors of the 25 acute care hospitals in the system.

During her tenure at the former hospital, she saw a reduction of >60% in surgical site infections within the first year after initiating MRSA and methicillin-sensitive *S aureus* screening using on-demand PCR. Two months into her new role at UHS, she conferred with the laboratory directors of the 6 hospitals who were using on-demand PCR to learn about their experiences with the technology. She arranged for these 6 laboratory directors to share their experiences with the remaining 19 laboratory directors. Certain themes resonated through each of the testimonials: efficiency, rapidity, and accuracy. Within a year, 6 additional laboratorians had partnered with their IPs and persuaded their c-suite to bring the technology to their facilities. She then decided that implementing the technology at the remaining facilities would best be accomplished by taking a corporate-driven approach. This involved collaborating with a laboratorian to look at the data supporting on-demand PCR’s impact on HAIs, isolation days, and hospital economics and bringing this information to a corporate summit that included everyone from the chief medical officer to risk management.

The data they found and used in their corporate pitch was compelling. A 2011 MRSA study conducted at Massachusetts General Hospital compared passive screening with active screening using traditional culture and active screening using PCR. The article demonstrates the impact each had on the discontinuation of contact precautions. Those patients in the PCR arm of the study had precaution discontinuation rates of 64% compared with 27% in the active screening with culture and 7% with the passive screening arm. Furthermore, the researchers estimated that the reduction in contact precaution days would save the facility $1.6 million for the active screening with the PCR group compared with $350.00 for active screening with culture and a mere $87,000 for the passive screening group. A 2011 study conducted at a small community hospital compared EIA and toxin A/B testing with PCR testing for *C difficile*. They documented a statistically significant reduction in tests ordered (118 for EIA, 38 for PCR) and patient isolation days (1,022 for EIA, 364 for PCR) when PCR technology was used.

After seeing a community hospital study reporting that 18% of the facility’s hospital days were devoted to isolation, the infection prevention director of UHS decided to look internally at their own isolation day rates within 7 of their hospitals. Although the UHS rates were lower (7%) than the study rate, they identified that within the 3-month period they monitored for contact (MRSA, vancomycin-resistant *Enterococcus*, etc), special contact (*C difficile*), droplet (influenza), and airborne negative pressure (*Mycobacterium tuberculosis* [MTB]) isolation days, there were some interesting discrepancies. For example, they identified that during those 3 months, there were only 6 real MTB cases. If each of those patients were isolated for a week, they would have accounted for 42 MTB isolation days, in fact there were a total of 274 MTB isolation days during that period, demonstrating rule-out MTB cases on presumptive airborne precautions.

Additionally, using a template published in the *Journal of American Medical Association* in 2013, the director had the IP from each facility in the UHS system estimate the financial impact of HAIs at their hospital. These numbers combined with the facilities’ CMS penalty figures successfully demonstrated to the corporate structure that capturing some of these expenses in the preventative arm of the system’s budget was in their best interest. The $24,900 to $174,400 investment in on-demand PCR equipment, depending on testing capacity, was deemed an expense that would easily be recouped in savings from averted HAIs, particularly given the fact that 1 on-demand system could test for multiple organisms. As a result, by June of 2015, every facility within the system had acquired on-demand PCR technology.

The next phase in the partnership, currently underway, is to standardize the screening protocols for high-risk surgeries (eg, joints, cardiac), MTB testing, and *C difficile* testing that use this new technology. As these protocols are developed, they will be mapped into algorithms designed to establish each step in the screening process such that any breakdown in the protocol could easily be identified and addressed.
surveillance, reduction in isolation days, streamlined microbiology laboratory procedures, and appropriate antimicrobial treatment—all of which contribute to optimal health care delivery.

A ROADMAP FOR IPS AND LABORATORIANS

It is evident from these 3 examples that communication and collaboration between IPs and laboratorians helped effect changes within their facilities, resulting in more efficient and cost-effective infection prevention programs and therefore high-value patient outcomes. With approximately 70% of information used by health care providers to make medical decisions originating from the laboratory, the value of building a relationship with the laboratorians is undeniable. However, for those IPs who have not yet entered into such a partnership with their laboratorians, it can be difficult to determine how to initiate this relationship building. A number of IPs

---

**Fig 1.** Universal Health Services methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-sensitive *S. aureus* (MSSA) preoperative algorithm. Reprinted with permission. CHG, chlorhexidine gluconate; Rx, treatment.
have shared their ideas for enhancing this collaboration in the literature,\textsuperscript{5,6,17} but as evidenced by the joint APIC/American Society for Microbiology survey of IPs and laboratorians,\textsuperscript{3} the gap between the 2 departments remain.

The focus group of IPs and laboratorians that convened during the 2015 APIC conference to address the need for this collaboration identified their experience-based recommendations for creating it:

- **Train together:** Having new IPs spend time at the beginning of their careers in the microbiology laboratory can not only foster better communication between the individuals in the departments, but it also help familiarize the IPs with the logistics and processes behind each test ordered. One IP in the focus group described how every new member of their IP team spends the first 2 weeks on the job in the laboratory, familiarizing themselves with the laboratory procedures and personnel.

- **Establish a schedule:** Creating a schedule of regular meetings between IPs and laboratorians will ensure a consistent exchange of information. One IP from the focus group reported that these regular meetings allowed for discussion about trends the laboratory was detecting in culture results and outlier pathogens that may not have come to the infection prevention team’s attention. She would schedule these meetings just prior to every regular infection prevention committee meeting so that she could share this information with the infection prevention team at large on a regular basis.

- **Run the numbers:** IPs and laboratorians must cull isolation days, average daily bed cost, infection rate, and CMS penalty data and compare that with any expense to be incurred by a change in technology or protocol that they wish to implement. The bottom line for the c-suite is the financial bottom line; therefore, presenting a strong economic case is critical.

- **Share the burden:** Costs incurred from changes in technology can be burdensome to a laboratory department. This economic burden can be shared across departments—from microbiology to infectious disease to infection prevention—all of whom are seeking to achieve the same end result.

- **Expand the committee:** Including laboratorians in infection control committees creates shared vigilance and awareness for everything from procedural delays to cluster outbreaks. This is particularly important for facilities with off-site laboratories where face-to-face interaction between the IP and laboratorian is limited. An IP from the focus group described how bringing the laboratorian to the unit where a cluster outbreak was occurring was pivotal in identifying the source of the outbreak, given the laboratorian’s expert knowledge of the microorganism.

No one department within a health care facility truly operates alone. Each department is working toward the common goal of delivering the highest possible standard of health care delivery, but that goal is clearly more readily obtained when departments pool resources and maintain open lines of communication. IPs and laboratorians must extend their own collaboration to include other departments. Working with the pharmacology and infectious disease departments to look at pathogen infection rates and how they compare with antibiotic usage rates, developing antibiograms, and tracking resistance patterns are all crucial elements of antimicrobial stewardship.\textsuperscript{5,6,17} Similarly, educating nursing staff regarding the science behind testing modalities and result interpretation can facilitate efficient patient management with those on the frontline of care.\textsuperscript{17} As epidemiologist Kathy Aureden stated, “Critical thinking is enhanced through discussion with a knowledgeable colleague.”\textsuperscript{118} The challenges posed by HAIs today and the challenges that lie ahead will demand a collaborative effort on the part of all those engaged in health care delivery.

### References


8. The American Society for Microbiology. The marriage of clinical microbiology and clinical chemistry: a technological exchange of vows and partnerships. Presented at: 115th General Meeting of the American Society for Microbiology; June 2015; New Orleans, LA.


